摘要
目的探讨拓扑异构酶Ⅱ在乳腺癌组织中的表达规律及在乳腺癌治疗中的预测价值。方法应用SP免疫组织化学方法,检测资料完整的100例浸润性乳腺癌组织标本。结果拓扑异构酶Ⅱ在100例浸润乳腺癌组织中表达的阳性率为48.0%,其与乳腺癌淋巴结转移?HER-2蛋白表达密切相关(P<0.05),而与患者年龄?月经情况、肿瘤大小、临床分期、组织学分级、ER状态无相关(P>0.05)。结论拓扑异构酶Ⅱ在乳腺癌组织中的高表达与乳腺癌的发生发展转移密切相关,其在乳腺癌的治疗和预后中可能起重要作用。
Objective To explore the regularity of expression of TOP Ⅱ in the breast cancer and its prognostic valument in the treatment of the breast cancer. Methods The expression of TOP Ⅱ was measured by immmunohisto- chemical assay in 100 eases of infiltrative type of breast carcinoma tissue all which have complete dates. Results The positive expression rates of TOP Ⅱ was 48.0% in the breast carcinoma , overexpression of TOP Ⅱ was significantly cor- related with axillary lymphonodus metastasis, expression of HER - 2 （ P 〈 0.05 ）, but it was insignificantly correlated with ages, menstruatiion, clinical TNM stage, tumor size, histologic grade, ER （ P 〉 0.05 ）. Conclusions The overex- pression of TOP Ⅱ was closed correlated with the development and metastasis of breast carcinoma , TOP Ⅱ may play a certain role in evalution prognosis and clinical treatment.
出处
《医学信息（手术学分册）》
2008年第12期1059-1061,共3页
Medical Information Operations Sciences Fascicule
关键词
拓扑异构酶
乳腺癌
免疫组织化学
topoisomerase Ⅱ
breast cancer
immunohistochemistry
